Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT07583862 · ClinicalTrials.gov registry record · Phase 2

The Effects of Timolol On Healing and Cosmesis of Mohs Scalp Wounds: An Open Label Trial

A Phase 2 study, sponsored by Geisinger Clinic.

Not yet
Registry status
Phase 2
Development phase
40
Enrollment target

NCT07583862: Clinical Trial Phase 2 study, sponsored by Geisinger Clinic.

NCT07583862 is a Phase 2 study that has not yet begun recruiting, run by Geisinger Clinic. The registered enrollment target is 40 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (70% lower). According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT07583862, a Phase 2 study, has not yet begun recruiting, sponsored by Geisinger Clinic.

NOT YET RECRUITING
Registry status
Phase 2
Development phase
40 participants
Enrollment target

Study Summary

The goal of this study clinical trial is to learn if topical timolol can accelerate healing and improve the cosmetic appearance of surgical wounds on the scalp following Mohs surgery. It will include Geisinger patients 18 year or older who undergo Mohs surgery of the scalp with planned wound healing by secondary intent. The main questions in aim to answer are: 1. Compare wound healing speed between patients treated with topical timolol and those receiving standard wound care only. 2. Compare cosmetic outcomes using topical timolol and standard wound care. 3. Evaluate the impact of topical timolol on the number of unplanned follow-up visits and calls related to delayed wound healing. Participants will be asked use either topical timolol or use standard wound care to treat their Mohs surgery scalp wound. They will follow-up around 4, 8 and 12 weeks.

Primary Outcome

Percentage of patients achieving complete re-epithelialization at 12 weeks

Interventions

  • DRUG Normal Saline
  • DRUG Topical Timolol

Trial Details

FieldValue
Enrollment Target 40 participants
Start Date 2026-07-01
Est. Completion 2029-03
Phase Phase 2
Geisinger Clinic

107 total trials

What is known before NCT07583862 opens enrollment

NCT07583862 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 40 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (70% lower).

The record links to 0 conditions, and to 2 interventions - of which Normal Saline is the first listed.

NCT07583862 does not publish any study locations in the registry export this page uses.

Frequently Asked Questions

What is clinical trial NCT07583862 about?

NCT07583862 is a clinical study titled "The Effects of Timolol On Healing and Cosmesis of Mohs Scalp Wounds: An Open Label Trial". The goal of this study clinical trial is to learn if topical timolol can accelerate healing and improve the cosmetic appearance of surgical wounds on the scalp following Mohs surgery. It will include Geisinger patients 18 year or older who undergo Mohs surgery of the scalp with planned wound healing...

What is the current status of trial NCT07583862?

This trial is currently not yet recruiting. It is a Phase 2 study. The enrollment target is 40 participants. The study started on 2026-07-01. Estimated completion is 2029-03.

What interventions are being tested in trial NCT07583862?

The interventions under investigation include: Normal Saline (DRUG), Topical Timolol (DRUG).

Who is sponsoring clinical trial NCT07583862?

This trial is sponsored by Geisinger Clinic, which has 107 total clinical trials registered on ClinicalTrials.gov.

How this trial's enrollment target compares

Where NCT07583862's enrollment target sits among peer trials

40 1362nd of 2000 higher than 542 of 2,000 other Phase 2 trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT01306019 · 40 participants · Phase 1

    Lentiviral Gene Transfer for Treatment of Children Older Than Two Years of Age With X-Linked Severe Combined Immunodeficiency (XSCID)

  • NCT01608152 · 40 participants

    Development of a Video Game for the Improvement of Outcomes in Stem Cell Transplant Survivors

  • NCT01668082 · 40 participants · NA

    An Investigation of Brain Tumor Metabolism in Patients Undergoing Surgical Resection

  • NCT02015013 · 40 participants · Phase 2

    Hematopoietic Stem Cell Mobilization in Idiopathic CD4 Lymphocytopenia Patients and Healthy Controls for the Study of T Cell Maturation and Trafficking in Murine Models

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT07583862, the US trial registry maintained by the National Library of Medicine. NCT07583862 (small enrollment · none site footprint · not yet recruiting) retrieved and formatted by PlainTrial, see methodology.